Georgia Research Alliance

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Focused Cryo is a healthcare company that develops a smart cryoablation system that provides better spatiotemporal control. These benefits represent a significant improvement in the treatment of Type 2 diabetes, obesity, and other ailments that are addressed with the cryoablation of nerves and ganglia. The company is based in Kennesaw, Georgia.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in real-time cellular activity monitoring for drug discovery and biological research. The company serves academic institutions and pharmaceutical companies by offering innovative systems designed for continuous and non-invasive measurement of cellular activities. Its flagship technology, RESIPHER, utilizes high-resolution optical oxygen sensors to monitor oxygen consumption within standard multi-well plates. This system provides researchers with valuable insights into cell culture experiments, streaming data directly to a user-friendly web application. By enhancing the understanding of cellular environments, Lucid Scientific aims to accelerate drug discovery and advance basic biological research.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in real-time cellular activity monitoring for drug discovery and biological research. The company serves academic institutions and pharmaceutical companies by offering innovative systems designed for continuous and non-invasive measurement of cellular activities. Its flagship technology, RESIPHER, utilizes high-resolution optical oxygen sensors to monitor oxygen consumption within standard multi-well plates. This system provides researchers with valuable insights into cell culture experiments, streaming data directly to a user-friendly web application. By enhancing the understanding of cellular environments, Lucid Scientific aims to accelerate drug discovery and advance basic biological research.

MapHabit, Inc. is a company that specializes in developing solutions for individuals with memory impairments by utilizing visual maps to engage the brain's habit system and foster healthy routines. Founded in 2018 and based in Decatur, Georgia, MapHabit offers a mobile app that enables patients, their families, and care providers to create, track, and share personalized daily plans and activities. The app also provides valuable data analytics for care providers, facilitating research and the establishment of localized support groups and customized events. By offering a personalized, visual task mapping system, MapHabit simplifies care management for both patients and providers, helping individuals with various disorders navigate their daily activities effectively.

MapHabit, Inc. is a company that specializes in developing solutions for individuals with memory impairments by utilizing visual maps to engage the brain's habit system and foster healthy routines. Founded in 2018 and based in Decatur, Georgia, MapHabit offers a mobile app that enables patients, their families, and care providers to create, track, and share personalized daily plans and activities. The app also provides valuable data analytics for care providers, facilitating research and the establishment of localized support groups and customized events. By offering a personalized, visual task mapping system, MapHabit simplifies care management for both patients and providers, helping individuals with various disorders navigate their daily activities effectively.

Lucid Scientific, Inc. is a biotechnology tools company based in Atlanta, Georgia, specializing in real-time cellular activity monitoring for drug discovery and biological research. The company serves academic institutions and pharmaceutical companies by offering innovative systems designed for continuous and non-invasive measurement of cellular activities. Its flagship technology, RESIPHER, utilizes high-resolution optical oxygen sensors to monitor oxygen consumption within standard multi-well plates. This system provides researchers with valuable insights into cell culture experiments, streaming data directly to a user-friendly web application. By enhancing the understanding of cellular environments, Lucid Scientific aims to accelerate drug discovery and advance basic biological research.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for inflammatory diseases, cancer, and autoimmune disorders. Established in 2007 and headquartered in Atlanta, Georgia, the company is engaged in developing drug compounds that manipulate immune cell migration and activation. One of its key products, CTX-4430, is a small-molecule drug designed to inhibit the enzyme Leukotriene A4 hydrolase in immune cells, targeting conditions such as cystic fibrosis and moderately severe acne. Celtaxsys aims to provide innovative treatments that address the protective mechanisms of certain tumors, thereby enhancing the immune response against cancer and managing serious inflammatory conditions.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

Urjanet, Inc. is a company that offers a cloud-based platform designed to streamline access to utility data. By connecting directly to utility providers, Urjanet acquires and normalizes utility bills and interval data, enabling organizations to automate data collection and enhance decision-making processes. Its offerings include a range of data-as-a-service solutions, such as automated access to utility bill data, granular measurements of energy consumption, and advanced metering infrastructure data. The platform also provides tools for users to submit utility credentials securely, as well as alerts for billing and consumption irregularities. Urjanet's data services support business intelligence, energy management, accounting, and procurement, helping organizations improve financial performance, energy efficiency, and sustainability. Founded in 2009 and headquartered in Atlanta, Georgia, with an additional office in Chennai, India, Urjanet aims to transform how organizations utilize utility data across various industries.

NatGlycan is a biotech corporation focusing on large-scale natural glycans. It introduces proprietary glycan extraction techniques making possible the large-scale preparation of natural glycans. NatGlycan is dedicated to providing high-quality glycans and technical services to industry and the community. The company was co-founded by two preeminent professors at Emory University in Atlanta USA.

MoQuality Inc., founded in 2014 and headquartered in Atlanta, Georgia, specializes in artificial intelligence-driven mobile testing solutions. The company aims to enhance app quality and improve user experiences by providing tools that simplify and accelerate the testing process. MoQuality's flagship product, Barista, offers a scriptless test-automation experience, leveraging AI to generate user-centric test scenarios that automate testing across various mobile platforms and real devices. This platform allows developers to identify and address issues before releasing their applications, ensuring high-quality performance for both Android and iOS apps. MoQuality is supported by investors including Amity Ventures, Cox Enterprises, and Techstars.

Accuitis, Inc. is a pre-clinical-stage biopharmaceutical company founded in 2011 and based in Alpharetta, Georgia. The company specializes in the acquisition, development, and marketing of pharmaceuticals aimed at niche, orphan, and underserved disease states. Accuitis focuses on creating drug therapies for conditions such as rosacea, as well as other topical skin and eye diseases. Its product offerings include a proteasome inhibitor for rosacea treatment, alongside therapeutics targeting skin aging, acne, and dry eye conditions. Through its targeted approach, Accuitis aims to address significant unmet medical needs in these areas.

QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.

QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.

LymphaTech is a healthcare technology company based in Atlanta, Georgia, focused on treating and preventing lymphedema. Founded in 2014, the company offers a 3D body scanning solution that measures leg circumference to create detailed three-dimensional models of limbs. This technology enables healthcare providers to diagnose lymphedema more effectively and monitor changes in limb volume over time. The 3D scans can be conducted in various settings, including at home or in a doctor's office, facilitating early detection of symptoms and timely intervention. By improving diagnosis and treatment options, LymphaTech's innovative approach aims to enhance the quality of life for patients, particularly breast cancer survivors, while providing valuable tools for clinicians and physical therapists.

Clearside Biomedical, Inc. is a biopharmaceutical company focused on developing treatments for serious eye diseases with the aim of restoring and preserving vision. Founded in 2011 and headquartered in Alpharetta, Georgia, the company specializes in a proprietary ocular microinjection platform that allows for targeted delivery of therapeutic products to specific compartments of the eye. This innovative approach includes the use of the SCS Microinjector for administering therapies directly into the suprachoroidal space, enabling a non-surgical, repeatable procedure. Among its product pipeline, Clearside is developing XIPERE, a triamcinolone acetonide injectable suspension for macular edema, and CLS-AX, an axitinib for suprachoroidal injection. The company is dedicated to advancing pharmacological therapies for sight-threatening conditions by ensuring precise and effective treatment delivery.

QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.

Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.

MedShape is a privately held medical device company founded in 2005 based on a portfolio of proprietary surgical solutions that use its patented adaptive shape memory healing technologies to address the increasing demand for improved joint fusion, sports medicine, and musculoskeletal trauma products. MedShape® has enjoyed long-term support from Hills Capital Management, the Georgia Research Alliance (GRA), the National Science Foundation (NSF), the National Institutes of Health (NIH), and In-Q-Tel.

QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.

QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.

QUE Oncology, Inc. is a biotechnology company based in Atlanta, Georgia, founded in 2013 through a collaboration between Emory University and The University of Queensland's research commercialization company, UniQuest. The company focuses on developing innovative drug therapies for cancer, particularly breast and prostate cancer, by licensing intellectual property from both institutions. QUE's leading drug candidate, Q-122, is currently in Phase 1b clinical development and targets hot flashes in women undergoing anti-estrogen therapy for breast cancer. This compound is a non-hormonal, orally bioavailable small molecule designed to alleviate moderate to severe vasomotor symptoms, including night sweats. QUE Oncology's research pipeline also encompasses projects related to prostate cancer, melanoma, and cancer pain, aiming to meet significant unmet medical needs in oncology.

Metaclipse Therapeutics is an early-stage biotechnology company focused on developing personalized cancer immunotherapies. Founded in 2010 and based in Atlanta, Georgia, the company is engaged in the creation of Membrex, a novel treatment that utilizes modified tumor-membrane vesicles derived from a patient's own tumor tissue. These vesicles are augmented with clinically proven immunostimulatory proteins using a proprietary method. The resulting product is designed to activate the body's immune system, enabling it to target and attack metastatic cancer cells effectively. Metaclipse's therapies are aimed at treating various cancer types, including breast, prostate, renal, melanoma, and lymphoma. The company plans to commercialize its products through licensing agreements with major pharmaceutical firms after establishing their safety and efficacy.

Metaclipse Therapeutics is an early-stage biotechnology company focused on developing personalized cancer immunotherapies. Founded in 2010 and based in Atlanta, Georgia, the company is engaged in the creation of Membrex, a novel treatment that utilizes modified tumor-membrane vesicles derived from a patient's own tumor tissue. These vesicles are augmented with clinically proven immunostimulatory proteins using a proprietary method. The resulting product is designed to activate the body's immune system, enabling it to target and attack metastatic cancer cells effectively. Metaclipse's therapies are aimed at treating various cancer types, including breast, prostate, renal, melanoma, and lymphoma. The company plans to commercialize its products through licensing agreements with major pharmaceutical firms after establishing their safety and efficacy.

Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia. It provides comprehensive services to the pharmaceutical, biotechnology, clinical, academic, and government sectors, focusing on clinical trials, diagnostic testing, and research. The company specializes in high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (including NGS and Sanger), genotyping, and epigenomic analysis. These services adhere to CLIA and GLP standards and cater to various markers such as DNA, mRNA, miRNA, and methylation. AKESOgen's clientele includes notable organizations like the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente. Incorporated in 2010, AKESOgen operates as a subsidiary of Tempus Labs, Inc. and has a primary focus on oncology and personalized medicine.

Metaclipse Therapeutics is an early-stage biotechnology company focused on developing personalized cancer immunotherapies. Founded in 2010 and based in Atlanta, Georgia, the company is engaged in the creation of Membrex, a novel treatment that utilizes modified tumor-membrane vesicles derived from a patient's own tumor tissue. These vesicles are augmented with clinically proven immunostimulatory proteins using a proprietary method. The resulting product is designed to activate the body's immune system, enabling it to target and attack metastatic cancer cells effectively. Metaclipse's therapies are aimed at treating various cancer types, including breast, prostate, renal, melanoma, and lymphoma. The company plans to commercialize its products through licensing agreements with major pharmaceutical firms after establishing their safety and efficacy.

Cambium Medical Technologies, founded by four blood industry luminaries out of Emory University, Atlanta, Georgia (USA)--is focused on the development and commercialization of regenerative therapies derived from novel processed human platelets. Cambium is developing Elate Ocular a standardized, commercialized platelet derived biologic eye drop for dry eye syndrome (keratoconjunctivis sicca) as its first FDA approved therapy. Elate Ocular is an investigational drug and is not yet approved for sale in or outside the United States.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia. It provides comprehensive services to the pharmaceutical, biotechnology, clinical, academic, and government sectors, focusing on clinical trials, diagnostic testing, and research. The company specializes in high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (including NGS and Sanger), genotyping, and epigenomic analysis. These services adhere to CLIA and GLP standards and cater to various markers such as DNA, mRNA, miRNA, and methylation. AKESOgen's clientele includes notable organizations like the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente. Incorporated in 2010, AKESOgen operates as a subsidiary of Tempus Labs, Inc. and has a primary focus on oncology and personalized medicine.

NeurOp, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing treatments for central nervous system disorders. Founded in 2002, NeurOp specializes in creating small molecules that target specific subunits of neuronal N-methyl-D-aspartate (NMDA) receptors. Its research addresses a range of conditions, including major depression, neuropathic pain, ischemia (stroke), schizophrenia, Alzheimer’s disease, and Parkinson’s disease. The company aims to harness the therapeutic potential of these compounds to improve outcomes for patients suffering from various CNS-related ailments.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia. It provides comprehensive services to the pharmaceutical, biotechnology, clinical, academic, and government sectors, focusing on clinical trials, diagnostic testing, and research. The company specializes in high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (including NGS and Sanger), genotyping, and epigenomic analysis. These services adhere to CLIA and GLP standards and cater to various markers such as DNA, mRNA, miRNA, and methylation. AKESOgen's clientele includes notable organizations like the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente. Incorporated in 2010, AKESOgen operates as a subsidiary of Tempus Labs, Inc. and has a primary focus on oncology and personalized medicine.

AKESOgen, Inc. is an integrated genomics, genetics, and biobanking company based in Norcross, Georgia. It provides comprehensive services to the pharmaceutical, biotechnology, clinical, academic, and government sectors, focusing on clinical trials, diagnostic testing, and research. The company specializes in high-throughput biomarker profiling, DNA and RNA extractions, cytogenomic arrays, sequencing (including NGS and Sanger), genotyping, and epigenomic analysis. These services adhere to CLIA and GLP standards and cater to various markers such as DNA, mRNA, miRNA, and methylation. AKESOgen's clientele includes notable organizations like the CDC, the U.S. Department of Veterans Affairs, the American Cancer Society, and Kaiser Permanente. Incorporated in 2010, AKESOgen operates as a subsidiary of Tempus Labs, Inc. and has a primary focus on oncology and personalized medicine.

Whisper Communications is an Atlanta-based company that specializes in wireless networking services, utilizing innovative technologies derived from research at the Georgia Institute of Technology. The firm has developed a patent-pending encoding methodology that enhances data security by ensuring that signals transmitted beyond a designated area, referred to as the "cone of silence," are rendered useless to potential eavesdroppers. This approach focuses on physical layer security, where data security is directly linked to proximity to the data source. By enabling IT companies to monitor, track, and control devices at fixed locations, Whisper Communications aims to advance the field of data security in wireless communications.

NeurOp, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing treatments for central nervous system disorders. Founded in 2002, NeurOp specializes in creating small molecules that target specific subunits of neuronal N-methyl-D-aspartate (NMDA) receptors. Its research addresses a range of conditions, including major depression, neuropathic pain, ischemia (stroke), schizophrenia, Alzheimer’s disease, and Parkinson’s disease. The company aims to harness the therapeutic potential of these compounds to improve outcomes for patients suffering from various CNS-related ailments.

Metaclipse Therapeutics is an early-stage biotechnology company focused on developing personalized cancer immunotherapies. Founded in 2010 and based in Atlanta, Georgia, the company is engaged in the creation of Membrex, a novel treatment that utilizes modified tumor-membrane vesicles derived from a patient's own tumor tissue. These vesicles are augmented with clinically proven immunostimulatory proteins using a proprietary method. The resulting product is designed to activate the body's immune system, enabling it to target and attack metastatic cancer cells effectively. Metaclipse's therapies are aimed at treating various cancer types, including breast, prostate, renal, melanoma, and lymphoma. The company plans to commercialize its products through licensing agreements with major pharmaceutical firms after establishing their safety and efficacy.

NeurOp, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing treatments for central nervous system disorders. Founded in 2002, NeurOp specializes in creating small molecules that target specific subunits of neuronal N-methyl-D-aspartate (NMDA) receptors. Its research addresses a range of conditions, including major depression, neuropathic pain, ischemia (stroke), schizophrenia, Alzheimer’s disease, and Parkinson’s disease. The company aims to harness the therapeutic potential of these compounds to improve outcomes for patients suffering from various CNS-related ailments.

NeurOp, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing treatments for central nervous system disorders. Founded in 2002, NeurOp specializes in creating small molecules that target specific subunits of neuronal N-methyl-D-aspartate (NMDA) receptors. Its research addresses a range of conditions, including major depression, neuropathic pain, ischemia (stroke), schizophrenia, Alzheimer’s disease, and Parkinson’s disease. The company aims to harness the therapeutic potential of these compounds to improve outcomes for patients suffering from various CNS-related ailments.

NeurOp, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing treatments for central nervous system disorders. Founded in 2002, NeurOp specializes in creating small molecules that target specific subunits of neuronal N-methyl-D-aspartate (NMDA) receptors. Its research addresses a range of conditions, including major depression, neuropathic pain, ischemia (stroke), schizophrenia, Alzheimer’s disease, and Parkinson’s disease. The company aims to harness the therapeutic potential of these compounds to improve outcomes for patients suffering from various CNS-related ailments.

NeurOp, Inc. is a biopharmaceutical company based in Atlanta, Georgia, focused on developing treatments for central nervous system disorders. Founded in 2002, NeurOp specializes in creating small molecules that target specific subunits of neuronal N-methyl-D-aspartate (NMDA) receptors. Its research addresses a range of conditions, including major depression, neuropathic pain, ischemia (stroke), schizophrenia, Alzheimer’s disease, and Parkinson’s disease. The company aims to harness the therapeutic potential of these compounds to improve outcomes for patients suffering from various CNS-related ailments.